A study of microRNAs as new prognostic biomarkers in anal cancer patients.

IF 2.7 3区医学 Q3 ONCOLOGY

Acta Oncologica Pub Date : 2024-06-20 DOI:10.2340/1651-226X.2024.27976

Olav Dahl, Mette Pernille Myklebust

{"title":"A study of microRNAs as new prognostic biomarkers in anal cancer patients.","authors":"Olav Dahl, Mette Pernille Myklebust","doi":"10.2340/1651-226X.2024.27976","DOIUrl":null,"url":null,"abstract":"Background: MicroRNA (MiR) influences the growth of cancer by regulation of mRNA for 50-60% of all genes. We present as per our knowledge the first global analysis of microRNA expression in anal cancer patients and their prognostic impact.Methods: Twenty-nine patients with T1-4 N0-3 M0 anal cancer treated with curative intent from September 2003 to April 2011 were included in the study. RNA was extracted from fresh frozen tissue and sequenced using NGS. Differentially expressed microRNAs were identified using the R-package DEseq2 and the endpoints were time to progression (TTP) and cancer specific survival (CSS).Results: Five microRNAs were significantly associated with 5-year progression free survival (PFS): Low expression of two microRNAs was associated with higher PFS, miR-1246 (100% vs. 55.6%, p = 0.008), and miR-135b-5p (92.9% vs. 59.3%, p = 0.041). On the other hand, high expressions of three microRNAs were associated with higher PFS, miR-148a-3p (93.3% vs. 53.6%, p = 0.025), miR-99a-5p (92.9% vs. 57.1%, p = 0.016), and let-7c-3p (92.9% vs. 57.1%, p = 0.016). Corresponding findings were documented for CSS.Interpretation: Our study identified five microRNAs as prognostic markers in anal cancer. MiR-1246 and microRNA-135b-5p were oncoMiRs (miRs with oncogene effects), while miR-148a-3p, miR- 99a-5p, and let-7c-3p acted as tumour suppressors in anal cancer patients.","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"456-465"},"PeriodicalIF":2.7000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11332526/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Oncologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2340/1651-226X.2024.27976","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: MicroRNA (MiR) influences the growth of cancer by regulation of mRNA for 50-60% of all genes. We present as per our knowledge the first global analysis of microRNA expression in anal cancer patients and their prognostic impact.

Methods: Twenty-nine patients with T1-4 N0-3 M0 anal cancer treated with curative intent from September 2003 to April 2011 were included in the study. RNA was extracted from fresh frozen tissue and sequenced using NGS. Differentially expressed microRNAs were identified using the R-package DEseq2 and the endpoints were time to progression (TTP) and cancer specific survival (CSS).

Results: Five microRNAs were significantly associated with 5-year progression free survival (PFS): Low expression of two microRNAs was associated with higher PFS, miR-1246 (100% vs. 55.6%, p = 0.008), and miR-135b-5p (92.9% vs. 59.3%, p = 0.041). On the other hand, high expressions of three microRNAs were associated with higher PFS, miR-148a-3p (93.3% vs. 53.6%, p = 0.025), miR-99a-5p (92.9% vs. 57.1%, p = 0.016), and let-7c-3p (92.9% vs. 57.1%, p = 0.016). Corresponding findings were documented for CSS.

Interpretation: Our study identified five microRNAs as prognostic markers in anal cancer. MiR-1246 and microRNA-135b-5p were oncoMiRs (miRs with oncogene effects), while miR-148a-3p, miR- 99a-5p, and let-7c-3p acted as tumour suppressors in anal cancer patients.

查看原文本刊更多论文

将微RNAs作为肛门癌患者新的预后生物标记物的研究。

背景：微RNA（MiR）通过调控50%-60%基因的mRNA来影响癌症的生长。据我们所知，我们首次对肛门癌患者的微RNA表达及其对预后的影响进行了全面分析：研究纳入了 2003 年 9 月至 2011 年 4 月期间接受根治性治疗的 29 例 T1-4 N0-3 M0 肛门癌患者。从新鲜冷冻组织中提取 RNA，并使用 NGS 进行测序。使用R软件包DEseq2鉴定了差异表达的microRNA，终点为进展时间（TTP）和癌症特异生存率（CSS）：结果：5个microRNA与5年无进展生存期（PFS）明显相关：miR-1246（100% vs. 55.6%，p = 0.008）和miR-135b-5p（92.9% vs. 59.3%，p = 0.041）这两个microRNA的低表达与较高的无进展生存期相关。另一方面，三种microRNA的高表达与较高的PFS相关，即miR-148a-3p（93.3% vs. 53.6%，p = 0.025）、miR-99a-5p（92.9% vs. 57.1%，p = 0.016）和let-7c-3p（92.9% vs. 57.1%，p = 0.016）。CSS也有相应的研究结果：我们的研究发现了五种作为肛门癌预后标志物的微RNA。miR-1246和microRNA-135b-5p是oncoMiRs（具有癌基因效应的miRs），而miR-148a-3p、miR- 99a-5p和let-7c-3p则是肛门癌患者的肿瘤抑制因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Oncologica 医学-肿瘤学

CiteScore

4.30

自引率

3.20%

发文量

301

审稿时长

3 months

期刊介绍： Acta Oncologica is a journal for the clinical oncologist and accepts articles within all fields of clinical cancer research. Articles on tumour pathology, experimental oncology, radiobiology, cancer epidemiology and medical radio physics are also welcome, especially if they have a clinical aim or interest. Scientific articles on cancer nursing and psychological or social aspects of cancer are also welcomed. Extensive material may be published as Supplements, for which special conditions apply.